Araştırma Makalesi

Assessment of the antinociceptive effects of cannabinoid receptor agonists SER 601 and L-759,633 in an acute pain model in rats

Cilt: 43 Sayı: 1 31 Mart 2021
Cumhuriyet Tıp Dergisi Kapak
Cumhuriyet Tıp Dergisi
PDF İndir
EN

Assessment of the antinociceptive effects of cannabinoid receptor agonists SER 601 and L-759,633 in an acute pain model in rats

Abstract

A poorly managed pain is associated with many negative results. These results disturb patients, their families and societies. Although opioid agents have extraordinary analgesic efficacy, they may cause serious adverse consequences. For medication of pain, there is a medical need to discover possible alternatives to opioids. In animal models of acute pain synthetic cannabinoid receptor agonists demonstrated analgesic effects. Selective activation of the cannabinoid 2 receptor in the rodent models does not cause psychotropic effects therefore CB2R agonists are an appealing target for the medication of pain and other pathologies. In this study we examined the antinociceptive activity of cannabinoid receptor 2 (CB2) agonists SER 601 and L-759,633 in different doses in rat models of acute pain using the hot plate and tail flick tests. These two agents exhibited dose-dependent antinociceptive effects in acute pain model. The analgesic effects of the administrated doses of L-759,633 and SER 601 reached their peak at 60 min. In the tail flick test, the antinociceptive effects of 3, 6 and 12 mg / kg SER601 in the acute pain were more than the L-759,633 groups at the same doses.

Keywords

Destekleyen Kurum

Cumhuriyet University Scientific Research Project

Proje Numarası

T-848

Teşekkür

This study was funded by Cumhuriyet University Scientific Research Project (T-848, Doctoral Thesis Project, CUBAP, Turkey).

Kaynakça

  1. 1. Steeds CE. The anatomy and physiology of pain. Surgery. 2009;27(12):507-511. doi:10.1016/j.mpsur.2009.10.013
  2. 2. Koneti KK, Jones M. Management of acute pain. Surg (United Kingdom). 2013;31(2):77-83. doi:10.1016/j.mpsur.2012.12.004
  3. 3. Cohen SP, Mao J. Neuropathic pain: Mechanisms and their clinical implications. BMJ. 2014;348. doi:10.1136/bmj.f7656
  4. 4. Khan A, Khan S, Kim YS. Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets. Curr Drug Targets. 2019;20(7):775-788. doi:10.2174/1389450120666190131114244
  5. 5. Katz N. The impact of pain management on quality of life. In: Journal of Pain and Symptom Management. Vol 24. J Pain Symptom Manage; 2002. doi:10.1016/S0885-3924(02)00411-6
  6. 6. Starowicz K, Finn DP. Cannabinoids and Pain: Sites and Mechanisms of Action. In: Advances in Pharmacology. Vol 80. Academic Press Inc.; 2017:437-475. doi:10.1016/bs.apha.2017.05.003
  7. 7. Koob GF. The neurobiology of addiction: A neuroadaptational view relevant for diagnosis. Addiction. 2006;101(SUPPL. 1):23-30. doi:10.1111/j.1360-0443.2006.01586.x
  8. 8. Yuill MB, Hale DE, Guindon J, Morgan DJ. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Mol Pain. 2017;13. doi:10.1177/1744806917728227

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Yayımlanma Tarihi

31 Mart 2021

Gönderilme Tarihi

31 Ocak 2021

Kabul Tarihi

28 Mart 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 43 Sayı: 1

DOI

https://doi.org/10.7197/cmj.870286

IZ

https://izlik.org/JA89UD92AL

Kaynak Göster

RIS / Bibtex
AMA
1.Joha Z, Yıldırım Ş, Saraç B. Assessment of the antinociceptive effects of cannabinoid receptor agonists SER 601 and L-759,633 in an acute pain model in rats. CMJ. 2021;43(1):41-48. doi:10.7197/cmj.870286